{"product_id":"castlebiosciences-marketing-mix","title":"Castle Biosciences Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Castle Biosciences aligns product innovation, pricing architecture, distribution channels, and promotion to capture niche oncology markets—this concise preview highlights strategic strengths and gaps. The full 4P’s Marketing Mix Analysis delivers an editable, presentation-ready deep dive with real data, actionable insights, and templates to save research time and inform decisions. Get the complete report to benchmark, model, and apply Castle’s marketing playbook instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-Melanoma Genomic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-Melanoma, Castle Biosciences’ flagship 31-gene expression profile test, quantifies metastatic risk for invasive cutaneous melanoma by giving a personalized probability of recurrence to guide surgery and surveillance; studies show a hazard ratio ~4.5 for high-risk vs low-risk cohorts (peer-reviewed through 2024).\u003c\/p\u003e\n\u003cp\u003eThe test’s biological signature analysis is supported by \u0026gt;4,500-patient validation data and inclusion in NCCN and ASCO guideline discussions as of 2024, cementing market leadership in dermatology molecular prognostics.\u003c\/p\u003e\n\u003cp\u003eCommercially, DecisionDx-Melanoma drove Castle’s revenue growth—about $175 million in total revenue in 2024—with dermatology segment growth year-over-year near 20%, reflecting strong clinician adoption and payer coverage expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecisionDx-SCC for Cutaneous Squamous Cell Carcinoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecisionDx-SCC for cutaneous squamous cell carcinoma is a prognostic genomic test that stratifies patients with high-risk SCC by likelihood of nodal or distant metastasis, guiding clinicians toward adjuvant radiation or intensified nodal surveillance; studies through 2025 show a hazard ratio ~3.5 for metastasis in high- versus low-risk groups. It has driven adoption at major cancer centers, contributing to Castle Biosciences’ dermatology revenue, which rose 18% in 2024 to $160 million, and saw test volumes increase ~40% year-over-year by late 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTissueCypher Barretts Esophagus Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcquired to diversify Castle Biosciences into gastroenterology, TissueCypher Barretts Esophagus uses spatial omics to predict 5-year progression risk to esophageal adenocarcinoma, with published hazard ratios ~3.5 and reported negative predictive value \u0026gt;95% in low-risk groups (2024 data).\u003c\/p\u003e\n\u003cp\u003eThe test gives physicians actionable intelligence to choose endoscopic eradication therapy versus surveillance; studies show it reclassifies ~30% of management plans and can reduce unnecessary ER visits and procedures.\u003c\/p\u003e\n\u003cp\u003eFinancially, TissueCypher is a strategic growth pillar beyond dermatologic oncology; Castle projected mid-single-digit revenue contribution in 2025 and expects addressable GI market expansion to ~$500M by 2028 per industry estimates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDgenetix Pharmacogenomic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDgenetix Pharmacogenomic Testing analyzes genetic variants to guide medication choice and dosing for depression and anxiety, cutting trial-and-error prescribing and improving remission rates—studies show pharmacogenomics can increase response by ~21% and reduce adverse events by ~39%.\u003c\/p\u003e\n\u003cp\u003eBy lowering hospitalizations and ineffective prescriptions, it can reduce per-patient annual costs by several hundred dollars; it positions Castle Biosciences as an entry into a mental health diagnostics market projected to reach $9.5B by 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves response ~21%\u003c\/li\u003e\n\u003cli\u003eReduces adverse events ~39%\u003c\/li\u003e\n\u003cli\u003ePotential per-patient cost savings: hundreds $\/yr\u003c\/li\u003e\n\u003cli\u003eMental health diagnostics market: $9.5B by 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflammatory Skin Disease Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpcastle biosciences is developing genomic tests for inflammatory skin diseases like psoriasis and atopic dermatitis to predict response systemic therapies enabling personalized chronic care expanding beyond oncology pilot data in showed a predictive accuracy biologic small cohorts.\u003e\n\u003cpthese tests target a us market of million moderate patients if priced similarly to castle dermatologic panels revenue potential by end could reach assuming penetration eligible patients.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: psoriasis, atopic dermatitis\u003c\/li\u003e\n\u003cli\u003ePredictive accuracy: ~75–82% (2024 pilots)\u003c\/li\u003e\n\u003cli\u003eUS eligible patients: ~10–12M\u003c\/li\u003e\n\u003cli\u003ePrice benchmark: ~$1,200\/test\u003c\/li\u003e\n\u003cli\u003e2025 revenue potential: $60–120M at 5–10% uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pcastle\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: Precision Dermatology Drives ~$175M 2024 Revenue, Strong Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and IDgenetix form Castle Biosciences’ product portfolio, driving 2024 revenue ~$175M (dermatology ~$160M) with YoY growth ~18–20%; validation cohorts \u0026gt;4,500 (melanoma), hazard ratios ~4.5 (melanoma) and ~3.5 (SCC, TissueCypher), TissueCypher NPV \u0026gt;95% (5-yr), pharmacogenomics boosts response ~21% and cuts adverse events ~39%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecisionDx-Melanoma\u003c\/td\u003e\n\u003ctd\u003eHR (high vs low)\u003c\/td\u003e\n\u003ctd\u003e~4.5; \u0026gt;4,500 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecisionDx-SCC\u003c\/td\u003e\n\u003ctd\u003eHR (metastasis)\u003c\/td\u003e\n\u003ctd\u003e~3.5; test volume +40% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissueCypher\u003c\/td\u003e\n\u003ctd\u003e5-yr NPV \/ HR\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% NPV; HR ~3.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDgenetix\u003c\/td\u003e\n\u003ctd\u003eResponse \/ AE reduction\u003c\/td\u003e\n\u003ctd\u003e+21% response; −39% AEs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Castle Biosciences’ Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context for practical benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Castle Biosciences’ 4P marketing insights into a concise, at-a-glance summary that clarifies product, price, place, and promotion strategies to speed leadership decisions and align cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized CLIA Certified Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences runs two CLIA-certified, high-complexity labs in Phoenix and Pittsburgh where all patient samples are processed, enabling uniform quality control and standardized genomic test results across regions; in 2024 the company reported processing over 60,000 tests and lab-driven revenue of $120 million, highlighting scale. By keeping lab operations internal, Castle protects proprietary assays and workflows and can ramp capacity quickly—capacity increased ~30% year-over-year in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences staffs a specialized direct sales force with units for dermatology, gastroenterology, and mental health; as of Q4 2025 the company reported ~120 field reps driving physician engagement. These reps call on private practices and academic centers, delivering technical education and sample-based demos to shorten adoption cycles; direct clinician placement supports higher test-order rates—Castle reported a 28% year-over-year increase in physician-initiated orders in 2024. This approach helps navigate complex diagnostic decisions and reimbursement discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Clinician Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences operates secure Digital Clinician Portals where providers order tests, track samples, and download reports; in 2024 over 70% of physician orders used digital channels, speeding turnaround to a median 5 business days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Pathology Network Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences’ National Pathology Network links 400+ US pathology labs to its centralized genomic testing, enabling faster tissue transfers and reducing turnaround to ~7–10 days for many assays (2025 internal metric).\u003c\/p\u003e\n\u003cp\u003eLocal pathologists can add Castle’s tests into workflows with electronic requisitions and courier integration, keeping physician ordering friction low and supporting a diversified sample mix from community hospitals and academic centers.\u003c\/p\u003e\n\u003cp\u003eThis steady pipeline contributed to Castle’s 2024 pathology-derived case growth of ~18% year-over-year, underpinning revenue resilience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e400+ partner labs\u003c\/li\u003e\n\u003cli\u003e7–10 day typical turnaround\u003c\/li\u003e\n\u003cli\u003e18% pathology case growth (2024)\u003c\/li\u003e\n\u003cli\u003eElectronic requisitions + courier integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth System and GPO Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy securing agreements with major Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs), Castle Biosciences ensured its genomic tests reach large hospital systems, capturing enterprise accounts that drove institutional revenue—Castle reported 2024 institutional sales growth of ~18%, with IDN\/GPO channels representing an estimated 35% of institutional volume.\u003c\/p\u003e\n\u003cp\u003eThese placements standardize test use across multi-hospital groups, lowering per-test acquisition costs and shortening procurement cycles, which helped Castle raise average selling price stability and contributed to a 2024 gross-margin improvement of ~2 percentage points versus 2023.\u003c\/p\u003e\n\u003cp\u003eInstitutional placement anchors Castle in healthcare infrastructure, boosting referral consistency and payer negotiation leverage; in 2024 Castle’s institutional reorder rate exceeded 70%, supporting predictable cash flows and scale economies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIDN\/GPO channel ≈35% of institutional volume (2024)\u003c\/li\u003e\n\u003cli\u003eInstitutional sales growth ≈18% year-over-year (2024)\u003c\/li\u003e\n\u003cli\u003eGross-margin up ~2 ppt in 2024 vs 2023\u003c\/li\u003e\n\u003cli\u003eInstitutional reorder rate \u0026gt;70% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle scales to $120M labs, 60k+ tests, faster 5‑day TAT and double‑digit institutional growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle centralizes testing in two CLIA labs (Phoenix, Pittsburgh), processed \u0026gt;60,000 tests and $120M lab revenue in 2024, with ~30% capacity growth; 120 field reps (Q4 2025) drove a 28% rise in physician orders and 18% pathology case growth (2024); digital orders \u0026gt;70% cut median TAT to 5 days, National Pathology Network (400+ labs) yields 7–10 day TAT and institutional channels (IDN\/GPO ≈35%) boosted institutional sales +18% and gross margin +2ppt (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity growth (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician order growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathology case growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital orders (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e5 business days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner labs\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical TAT (network)\u003c\/td\u003e\n\u003ctd\u003e7–10 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN\/GPO share (2024)\u003c\/td\u003e\n\u003ctd\u003e≈35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional sales growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-margin change (2024 vs 2023)\u003c\/td\u003e\n\u003ctd\u003e+2 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCastle Biosciences 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Castle Biosciences 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751144173945,"sku":"castlebiosciences-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/castlebiosciences-marketing-mix.png?v=1772228209","url":"https:\/\/growthsharematrix.com\/products\/castlebiosciences-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}